8 reports

  • Global IV fluid bags market by home 2015-2020 ($ millions)
  • Global IV fluid bags market by hospital

Smoking is the most significant risk factor for cancer, causing around ##% of global cancer deaths and ##% of global lung cancer deaths.

  • Parenteral Nutrition
  • World
  • B. Braun Medical
  • Baxter International Inc.
  • Hospira, Inc.

CANADA A. Market Analysis Current and Future Analysis Rising Incidence of Chronic Diseases: A Major Growth Driver Table ##: New Cancer Cases (in Thousands) in Canada by Gender for 2015 and 2016 (includes corresponding Graph/ Chart) Table ##: Age-Standardized Incidence Rate (Per ‘##

  • Parenteral Nutrition
  • United States
  • World
  • Company Sales
  • Market Size

Increasing prevalence of chronic conditions such as cancer unswervingly influences the use of parenteral nutrition across the globe.

  • OTC
  • Parenteral Nutrition
  • Pharmaceutical
  • Forecast

Growing population of cancer patients ##. ##. ##.

  • OTC
  • Parenteral Nutrition
  • Market Size

Cancer ##. ##. ##. ##. ##.

  • Nutrition
  • Parenteral Nutrition
  • Pharmaceutical
  • Forecast
  • Market Size

CANADA A. Market Analysis Outlook Rising Incidence of Cancer - A Business Case for Parenteral Nutrition Market Table ##: New Cancer Cases (in Thousands) in Canada by Gender for 2015 and 2016 (includes corresponding Graph/ Chart) Table ##: Age-Standardized Incidence Rate (Per ‘## People)

  • Parenteral Nutrition
  • Europe
  • United States
  • World
  • Company Sales

Cancer, Pancreatic Cancer, Pancreatitis Completed Phase I Interventional moxifloxacin hydrochloride University Hospital Freiburg Bayer AG ## Dec 2010 ## Dec 2014 ## ## DNA Gyrase (EC ##. ##. ##. ##) Inhibitor; DNA Topoisomerase IV (EC ##. ##. ##. ##) Inhibitor DNA Gyrase (EC ##. ##. ##. ##); DNA Topo

  • Clinical Trial
  • Parenteral Nutrition
  • World
  • Product Initiative
  • Shire plc

Cancer, Pancreatic Cancer, Pancreatitis Completed Phase I Interventional moxifloxacin hydrochloride Universitatsklinikum Freiburg Bayer AG ## Dec 2010 ## Dec 2014 ## ## DNA Gyrase (EC ##. ##. ##. ##) Inhibitor; DNA Topoisomerase IV (EC ##. ##. ##. ##) Inhibitor DNA Gyrase (EC ##. ##. ##. ##); DNA Top

  • Digestive System Disorder
  • Parenteral Nutrition
  • World
  • Product Initiative
  • Shire plc